pgn-edodm1
Nucleic acidexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 12, 2023 (NCT06204809)
Timeline
Indications
Studied for
Mechanism of action
- DystrophinANTISENSE INHIBITOR
DMD antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07220603 | Phase 2 | Oct 31, 2025 | PepGen Inc |
| NCT06667453 | Phase 2 | Oct 31, 2024 | PepGen Inc |
| NCT06204809 | Phase 1 | Dec 12, 2023 | PepGen Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PepGen Inc | For profit | 3 | 3 | 2 | 2023 |
1 organizations
Page 1 / 1